2-(2-Amino-5-bromobenzoyl)pyridine, C12H9BrN2O, is used in pharmaceutical manufacturing as a pharma-grade intermediate for bromazepam API synthesis and as a resolved reference marker in bromazepam finished-dose testing. The terminal dosage forms are bromazepam-containing tablets, capsules, granule intermediates, and, only in limited feasibility work, investigational parenteral presentations. The following scenarios set out the downstream uses and the associated control limits. This application scope is restricted to bromazepam-derived dosage forms because the input intermediate is not itself a final API in tablet, capsule, granule, or injection formulations.

Charging 2-(2-amino-5-bromobenzoyl)pyridine as the limiting reactant into a glass-lined reactor at 0–5 °C jacket temperature is standard for the initial N-acylation. A slight molar excess of chloroacetyl chloride, typically 1.05–1.10 mol per mol of input intermediate, is added over 2–3 h under nitrogen to maintain control of the exotherm; triethylamine at 1.05–1.10 mol equivalent is pre-charged or co-fed in dichloromethane to strip liberated HCl. The reaction endpoint is monitored by in-process HPLC at 210 nm and 254 nm, with the primary aromatic amine peak held at ≤1.0% area before proceeding. Ring closure with anhydrous ammonia in methanol at 2.5–3.0 mol equivalent is then run under reflux for 8–12 h, followed by vacuum distillation at ≤45 °C to concentrate the crude bromazepam base. Crystallization from isopropanol/water 60:40 to 70:30 v/v with cooling to 0–5 °C yields the isolated solid, which is washed and dried at 60 °C under vacuum to loss on drying ≤0.5% per Ph. Eur. 2.2.32. For this route the molar addition ratio is a synthetic input ratio, not a direct formulation ratio; regulatory control sits under ICH Q7 for API manufacturing, ICH Q3A(R2) for impurity accounting, and ICH M7 for the primary aromatic amine alert. The downstream process output at this stage is bromazepam API base; subsequent milling and blending convert that base into the oral solid dosage forms described below. Published yield data for production-scale bromazepam synthesis from this specific intermediate are limited, and the molar ratios above are representative operational envelopes for 1,4-benzodiazepine ring closure rather than a compendial monograph.

What residual limits apply when the intermediate remains in bromazepam tablets?

Once bromazepam API is isolated, the input intermediate is controlled as a starting-material impurity and as a possible ring-opening degradation product. In bromazepam tablets and capsules the relevant impurity thresholds follow ICH Q3B(R2) for a maximum daily dose ≤1 g: reporting at 0.1%, qualification at 0.2% or 2 mg total daily intake, whichever is lower. For the API itself, ICH Q3A(R2) sets reporting at 0.05%, identification at 0.10%, and qualification at 0.15% for daily doses ≤2 g. Because the intermediate contains a primary aromatic amine, ICH M7 mutagenic impurity assessment applies; the threshold of toxicological concern is 1.5 µg/day, and the percent limit in the drug substance or product must be back-calculated from the bromazepam dose strength. The analytical procedure is reversed-phase HPLC per Ph. Eur. 2.2.46 or USP 621; system suitability requires resolution between the intermediate and bromazepam of not less than 2.0, tailing factor ≤2.0, and spike recovery between 90% and 110%. A system suitability spiking concentration of 0.10% relative to bromazepam is used in transfer protocols, with calibration bracketing 0.02–0.20%. The downstream process is release and stability HPLC-DAD or LC-MS quantitation of retained production batches and finished-dose samples. The terminal product type controlled by this method is bromazepam tablets and capsules, including 3 mg and 6 mg strengths. Table 1 summarizes the impurity and solvent thresholds.

Jet-milling the crystallized bromazepam base derived from the input intermediate reduces particle size to a range that supports low-dose content uniformity in direct compression. Micronization in a pancake or loop jet mill with nitrogen at feed pressure 6–8 bar and grinding pressure 5–7 bar yields a target D90 of ≤20 µm and D50 of 5–10 µm; published data for bromazepam-specific micronization are limited, but these targets are consistent with low-dose oral solid APIs. Laser diffraction particle size analysis is performed per ISO 13320:2020, and powder flow is characterized per Ph. Eur. 2.9.36 before blending. Direct compression addition ratios are calculated from a core weight of 120–200 mg; a 3 mg bromazepam strength corresponds to 1.5–2.5% w/w active, and a 6 mg strength corresponds to 3.0–5.0% w/w active. A representative direct compression blend contains lactose monohydrate at 75–85% w/w, microcrystalline cellulose at 10–20% w/w, crospovidone at 2–5% w/w, colloidal silicon dioxide at 0.2–0.5% w/w, and magnesium stearate at 0.5–1.0% w/w. The active is pre-blended with an equal mass of lactose for 10 min in a tumble blender at 20–30 rpm, followed by final blending for 20–30 min; blend uniformity RSD should be ≤5.0% before compression. Tablets are compressed on a rotary press with compaction force 8–15 kN and target hardness 50–90 N. Compliance includes ICH Q6A for particle-size specification if the attribute is critical, USP 905 for uniformity of dosage units, and Ph. Eur. 2.9.40 for uniformity of content. The compression output is bromazepam tablets of 3 mg and 6 mg strength. Table 2 presents the common formulation envelope.

Forced Degradation Behavior of Bromazepam Derived from the Aminobenzophenone Intermediate

Stability-indicating HPLC methods require 2-(2-amino-5-bromobenzoyl)pyridine as a resolved reference marker for ring-opening hydrolysis and synthetic carryover. Bromazepam film-coated tablets and capsules are stressed under ICH Q1A(R2) and ICH Q1B conditions: 1 M hydrochloric acid at 60 °C for 24 h, 1 M sodium hydroxide at 60 °C for 24 h, 3% hydrogen peroxide at 25 °C for 6 h, and photolysis at not less than 1.2 million lux·h and 200 W·h/m². The stressed samples are compared with a spiked reference solution containing the intermediate at 0.05–0.15% relative to bromazepam; resolution between the two peaks must exceed 2.0, and peak purity must be confirmed by HPLC-DAD or LC-MS. The downstream process is method transfer from API release laboratories to finished-dose quality control laboratories, not the manufacture of a separate finished product. Mass balance in stressed samples is expected between 95% and 105%, and the degradant profile is reported under ICH Q3B(R2) thresholds. Compliance includes Ph. Eur. 2.2.46 for chromatographic separation, USP 621 for system suitability, and ICH Q1B for photostability. The stability-controlled article is bromazepam tablets and capsules supported by the resulting forced degradation data. Published data on bromazepam hydrolysis confirm the benzophenone intermediate as a ring-opened product; batch-specific mass balance and degradant identity should be re-verified for each formulation matrix because excipients can alter the degradation pathway.

If a high-shear wet granulation route is selected for bromazepam tablets instead of direct compression, the low-dose active is pre-blended with the dry excipients before liquid addition to avoid segregation. A high-shear granulator with bowl capacity 50–300 L, impeller speed 100–250 rpm, and chopper speed 1000–2000 rpm is charged with bromazepam, lactose monohydrate, and microcrystalline cellulose. Purified water or a 5% w/w povidone K30 binder solution is sprayed at 25–35% w/w of the dry powder mass over 5–10 min; the granulation endpoint is controlled by impeller power or torque rather than fixed time. Wet mass is passed through a 1.0 mm sieve and dried in a fluid-bed dryer with inlet air at 60 °C until loss on drying is 1.5–2.5%. The dried granules are screened through 0.8–1.0 mm, blended with crospovidone 2–4% w/w intragranular and 1–2% w/w extragranular, and lubricated with magnesium stearate 0.5–1.0% w/w for 3–5 min in a bin blender. Compression on a rotary press produces tablets at hardness 50–90 N; dissolution is tested under USP 711 apparatus 2 at paddle speed 50 rpm in 900 mL of pH 1.2 or pH 4.5 medium. Finished tablet strengths are bromazepam 3 mg and 6 mg. Compliance references include USP 905, Ph. Eur. 2.9.40, ICH Q6A, and ICH Q8(R2) for design-space verification. Batch-to-batch variance in granule bulk density is controlled because shifts above 0.05 g/mL may alter die fill weight and content uniformity.

Capsule Fill Weight Variability Originates in Intermediate Crystallite Size and Flow

Encapsulation of bromazepam derived from the same intermediate places stricter limits on bulk density and flow than tablet compression because dosator and tamping-pin machines respond differently to cohesive micronized powders. Addition ratios for hard gelatin capsule fill place bromazepam at 1.5–5.0% w/w in a fill weight of 120–200 mg; lactose monohydrate or mannitol is used as filler at 75–85% w/w, sodium starch glycolate at 2–4% w/w, colloidal silicon dioxide at 0.2–0.5% w/w, and magnesium stearate at 0.5–1.0% w/w. The active is pre-blended with 10–20% of the filler for 10 min in a low-shear tumble blender at 20–30 rpm, followed by final blending for 20–30 min; blend uniformity RSD should be ≤5.0% before encapsulation. Powder feed is controlled by bulk density and angle of repose measured per Ph. Eur. 2.9.36 and USP 1174; practical operating bands are bulk density 0.45–0.65 g/mL and flow through a 15–25 mm orifice, though published batch data for bromazepam capsule fill are limited. Capsule filling is performed on a tamping-pin machine with 5–10 tamping stations at 40,000–80,000 capsules/h or on a dosator machine; fill weight is checked every 15–20 min with target RSD ≤2.0%. Disintegration testing follows USP 701 or Ph. Eur. 2.9.1 in water at 37 ± 2 °C, with a 15 min limit for uncoated hard capsules. The encapsulation output is bromazepam capsules containing 3 mg or 6 mg active. Compliance includes USP 905, ICH Q3B(R2), and ICH Q6A for dissolution and disintegration acceptance criteria.

Roller compaction of bromazepam API derived from 2-(2-amino-5-bromobenzoyl)pyridine is used where aqueous granulation is undesirable because of hydrolytic sensitivity or where direct compression cannot overcome segregation. The active is pre-blended with microcrystalline cellulose 10–20% w/w, lactose monohydrate 75–85% w/w, crospovidone 2–4% w/w intragranular, and magnesium stearate 0.5–1.0% w/w; the blend is compacted on a roller compactor at roll pressure 4–10 MPa, roll speed 5–15 rpm, and gap setting 1.5–2.5 mm. Ribbons are milled through a 0.8–1.0 mm screen on a conical mill at 1000–1500 rpm, and the milled granules are blended with extragranular crospovidone 1–2% w/w before lubrication and compression. The dry-granulation output is bromazepam 3 mg and 6 mg tablets; the granule intermediate is not sold as a finished oral granule presentation. Compliance follows ICH Q6A for critical granule attributes, USP 905 for uniformity of dosage units, USP 711 for dissolution, and Ph. Eur. 2.9.38 for granule sieve distribution. Roller compaction reduces residual moisture risk but introduces a compactibility limit: ribbon solid fraction above 0.75 may reduce tablet hardness and should be avoided. Batch records monitor ribbon solid fraction, milled granule bulk density, and final tablet hardness 50–90 N. Published data for roller-compacted bromazepam tablets are limited; the stated ranges are operational starting points for low-dose benzodiazepine dry granulation.

Does parenteral formulation of bromazepam require different residual impurity limits?

Parenteral presentations of bromazepam are not defined in major pharmacopoeial monographs, so the injectable application of the intermediate-derived API is confined to feasibility screening rather than a marketed terminal product. When a parenteral formulation is screened, bromazepam base is typically dissolved in a co-solvent system containing propylene glycol 20–40% v/v, ethanol 10–20% v/v, and buffered water at pH 3.0–4.0; the API concentration is limited by solubility, and published data for this specific configuration is limited. The manufacturing route would require aseptic filtration through a 0.22 µm PVDF or PES filter after bulk solution adjustment, followed by terminal sterilization only if the solution remains chemically stable and particulate-free. Residual impurity limits for an injectable product would be driven by ICH Q3B(R2) based on daily dose, ICH Q3D(R2) for elemental impurities, and Ph. Eur. 2.6.14 for bacterial endotoxins; the endotoxin limit must be derived from the clinical dose and route and is not specified here. The terminal product type for this screening would be an investigational bromazepam parenteral solution; no compendial monograph currently defines this dosage form. For the input intermediate, the injectable-specific tests are not routine, and the commercial downstream remains oral tablet, capsule, and granule intermediates rather than a marketed injectable product. Compliance references for a prospective injectable screen are ICH Q3D(R2), Ph. Eur. 2.6.14, USP 85, and ICH M7. No further injectable-specific addition ratio can be given without a defined formulation and clinical dose.